Demographic and Clinical Assessment of Warfarin Treatment in Thromboembolic Disease

Abstract

Introduction: Warfarin is a widely prescribed oral anticoagulant used to prevent thromboembolic events. However, its therapeutic response varies significantly among individuals due to clinical and demographic factors. Personalized warfarin dosing is essential to minimize complications such as bleeding or clotting. This study aims to investigate the clinical and demographic factors that may influence the required weekly dose of warfarin in patients receiving anticoagulation therapy.

Materials and Methods: A cross-sectional study was conducted involving patients on warfarin therapy. Key variables collected included age, sex, body weight, INR (International Normalized Ratio), and platelet count. Data were analyzed to identify correlations between these variables and the weekly warfarin dose.

Results: Statistical analysis revealed that both body weight and age significantly influenced warfarin dose requirements. Higher body weight was associated with a higher therapeutic dose, whereas older age was associated with a lower dose requirement. No significant associations were found between warfarin dose and sex or platelet count.

Conclusion: Age and body weight are two critical demographic factors that should be considered when determining the optimal warfarin dose. Adjusting dosage based on these parameters may enhance therapeutic outcomes and reduce the risk of adverse events, supporting a more individualized approach to anticoagulation therapy.